Every material Form 8-K Charles River Laboratories filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Charles River Laboratories International reported third-quarter 2026 revenue of $982.7 million and increased its full-year guidance for revenue and non-GAAP earnings per share. The results were driven by a 4.7% increase in organic revenue and a lower tax rate, alongside a significant benefit from the reversal of acquired tax reserves.
Charles River reported second-quarter 2026 revenue of $1.00 billion, down 2.7% from a year earlier, and non-GAAP earnings per share of $3.02, down 3.2%. A $63.7 million loss on the CDMO and Cell Solutions divestiture produced a GAAP net loss of $(1.5) million, or $(0.03) per diluted share. The company raised its 2026 non-GAAP EPS guidance but lowered its GAAP EPS guidance.
Q2 revenue $1.00 billion, down 2.7% from $1.03 billion; organic revenue up 0.1%
GAAP net loss $(1.5) million, or $(0.03) per diluted share, vs. net income of $52.3 million, or $1.06, a year earlier
Non-GAAP EPS $3.02, down 3.2% from $3.12; non-GAAP operating margin 20.5% vs. 22.1%
2026 non-GAAP EPS guidance raised to $11.15–$11.45 from $10.80–$11.30; GAAP EPS guidance cut to $3.05–$3.35 from $5.35–$5.85
At its May 5, 2026 annual meeting, Charles River Laboratories shareholders elected all 12 director nominees, approved a new 2026 Long-Term Incentive Plan, approved executive pay on an advisory basis, and ratified PricewaterhouseCoopers LLP as auditor for fiscal 2026. The votes are routine annual-meeting matters with no change in financial results or guidance reported in this filing.
All 12 directors were elected to serve until the 2027 annual meeting; each received more votes for than against.
The 2026 Long-Term Incentive Plan was approved with 41,523,179 votes for and 2,561,994 against.
Advisory say-on-pay was approved with 41,356,139 votes for and 2,716,251 against.
PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal 2026 with 43,646,371 votes for.
Charles River reported first-quarter 2026 revenue of $995.8 million, up 1.2% from a year earlier but down 1.5% on an organic basis. The GAAP net loss was $14.8 million, or $0.30 per diluted share, mainly due to a $118.0 million loss on assets held for sale tied to the CDMO and Cell Solutions divestiture, which closed May 6, 2026. Non-GAAP EPS was $2.06, down 12.0%, and the company reaffirmed its 2026 organic revenue and non-GAAP EPS guidance while lowering its reported revenue outlook by about 50 basis points.
Revenue was $995.8 million, up 1.2%; organic revenue declined 1.5%.
GAAP net loss of $14.8 million, or $0.30 per diluted share, versus net income of $25.5 million, or $0.50, in Q1 2025.
Non-GAAP diluted EPS was $2.06, down 12.0% from $2.34 a year earlier.
2026 non-GAAP EPS guidance of $10.80 to $11.30 was reaffirmed; reported revenue outlook was cut by about 50 basis points on foreign exchange assumptions.
Charles River Laboratories appointed Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer, with a tentative start date of April 6, 2026. He succeeds interim CFO Michael G. Knell, who will remain as Chief Accounting Officer.
Coleman, 58, is currently CFO and Chief Administrative Officer of Premier, Inc. and previously served as CFO of DENTSPLY SIRONA and Integra Life Sciences.
Offer letter sets a base salary of $800,000 and a 2026 target bonus of 85% of base salary, pro-rated to his hire date.
Coleman receives a 2026 equity award with a grant value of $3,000,000 and a one-time new hire equity award of $3,500,000, plus a one-time cash award of $1,875,000.
Charles River Laboratories reported fourth-quarter 2025 revenue of $994.2 million, down 0.8% from a year earlier, and a GAAP net loss of $(276.6) million, or $(5.62) per diluted share, driven by non-cash impairments. Non-GAAP earnings per share fell 10.2% to $2.39, and the company guided 2026 non-GAAP earnings per share to $10.70 to $11.20, which it said would be an increase of about 4% to 9%.
Q4 2025 revenue was $994.2 million, down 0.8% from $1,002.5 million; organic revenue declined 2.6%.
Q4 GAAP net loss was $(276.6) million, or $(5.62) per diluted share, including $211.0 million of intangible asset impairments and a $165.0 million goodwill impairment.
Q4 non-GAAP diluted EPS was $2.39, down 10.2% from $2.66; non-GAAP operating margin fell to 18.1% from 19.9%.
2026 guidance: non-GAAP EPS of $10.70 to $11.20 and GAAP EPS of $6.30 to $6.80; guidance excludes planned divestitures of about 7% of annual revenue.
Charles River Laboratories said at a J.P. Morgan conference that demand for its Discovery and Safety Assessment business improved through the second half of 2025, with a preliminary fourth-quarter book-to-bill of about 1.1x. The company also signed an agreement to buy K.F. (Cambodia) Ltd. for about $510 million and is exercising an option to buy the remaining 79% of PathoQuest SAS for about $60 million, which it expects to help non-GAAP earnings per share.
Preliminary DSA net book-to-bill of approximately 1.1x in Q4 2025; the company says the figure may change once audited 2025 results are complete
K.F. (Cambodia) Ltd. purchase price about $510 million, expected to close early in Q1 2026, with accretion of about $0.25 to 2026 and $0.60 to 2027 non-GAAP EPS
PathoQuest SAS remaining 79% stake for €51.6 million (about $60 million), expected to close by end of Q1 2026
2026 outlook: top end of organic revenue growth ranges expected to be at least flat; incremental cost savings above $100 million
Charles River Laboratories announced that Chairman and CEO James Foster will step down, and Chief Operating Officer Birgit Girshick will become CEO, both effective May 5, 2026. Foster will remain a non-executive director, and Lead Independent Director Martin Mackay is expected to become Board Chair on the same date.
Birgit Girshick, current COO, to become CEO effective May 5, 2026, and to join the Board at the 2026 Annual Meeting
Base salary set at $1,200,000 effective February 1, 2026; initial equity grant with target value of $9,000,000
Severance if terminated without cause or for good reason before first anniversary of a change in control: three times salary plus target bonus
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Charles River Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →